Osteopontin expression profiles predict pathological and clinical outcome in breast cancer

Anticancer Research

Volumn 28, Issue 6 B, 2008, Pages 4105-4110

  Patani, Neill ^a   Jouhra, Fadi ^a   Jiang, Wen ^b   Mokbel, Kefah ^a,c  

^a Princess Grace Hospital   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Breast cancer; Mortality; Osteopontin; Survival

Indexed keywords

OSTEOPONTIN; OSTEOPONTIN A; OSTEOPONTIN B; OSTEOPONTIN C; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION;

BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; OSTEOPONTIN; PROTEIN ISOFORMS; RNA, MESSENGER; SURVIVAL RATE;

EID: 58149150066     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Tuck AB and Chambers AF: The role of osteopontin in breast cancer: clinical and experimental studies. J Mammary Gland Biol Neoplasia 6(4): 419-429, 2001.
2. He B, Mirza M and Weber GF: An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene 25: 2192-2202, 2006.
3. Mirza M, Shaughnessy E, Hurley JK et al: Osteopontin-c is a selective marker of breast cancer. Int J Cancer 122(4): 889-897, 2008.
4. Rodrigues LR, Teixeira JA, Schmitt FL et al: The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol Biomarkers Prev 16(6): 1087-1097, 2007.
5. Rudland PS, Platt-Higgins A, El-Tanani M et al: Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 62(12): 3417-3427, 2002.
6. Bramwell VH, Doig GS, Tuck AB et al: Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res 12: 3337-3343, 2006.
7. Singhal H, Bautista DS, Tonkin KS et al: Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 3(4): 605-611, 1997.
8. Zhang G, He B and Weber GF: Growth factor signaling induces metastasis genes in transformed cells: molecular connection between Akt kinase and osteopontin in breast cancer. Mol Cell Biol 23(18): 6507-6519, 2003.
9. Suzuki M, Mose E, Galloy C et al: Osteopontin gene expression determines spontaneous metastatic performance of orthotopic human breast cancer xenografts. Am J Pathol 171(2): 682-692, 2007.
10. Shevde LA, Samant RS, Paik JC et al: Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma, MDA-MB-435. Clin Exp Metastasis 23(2): 123-133, 2006.
11. Samant RS, Clark DW, Fillmore RA et al: Breast cancer metastasis suppressor 1 (BRMS1) inhibits osteopontin transcription by abrogating NF-kappaB activation. Mol Cancer 6: 6, 2007.
12. El-Tanani MK, Campbell FC, Crowe P et al: BRCA1 suppresses osteopontin-mediated breast cancer. J Biol Chem 281(36): 26587-26601, 2006.
13. Tuck AB, Chambers AF and Allan AL: Osteopontin overexpression in breast cancer: knowledge gained and possible implications for clinical management. J Cell Biochem 102(4): 859-868, 2007.
14. Cook AC, Tuck AB, McCarthy S et al: Osteopontin induces multiple changes in gene expression that reflect the six "hallmarks of cancer" in a model of breast cancer progression. MoI Carcinog 43(4): 225-236, 2005.
15. Standal T, Borset M and Sundan A: Role of osteopontin in adhesion, migration, cell survival and bone remodelling. Exp Oncol 26(3): 179-184, 2004.
16. Furger KA, Menon RK, Tuck AB et al: The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 1(5): 621-632, 2001.
17. Graessmann M, Berg B, Fuchs B et al: Chemotherapy resistance of mouse WAP-SVT/t breast cancer cells is mediated by osteopontin, inhibiting apoptosis downstream of caspase-3. Oncogene 26(20): 2840-2850, 2007.
18. Allan AL, George R, Vantyghem SA et al: Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer. Am J Pathol 169(1): 233-246, 2006.
19. Jiang WG, Douglas-Jones A and Mansel RE: Level of expression of PPAR-gamma and its co-activator (PPAR-GCA) in human breast cancer. Int J Cancer 106: 752-757, 2003.
20. Jiang WG, Watkins G, Lane J et al: Prognostic value of Rho family and rho-GDIs in breast cancer. Clin Cancer Res 9: 6432-6440, 2003.
21. Jiang WG, Watkins G, Fodstad O et al: Differential expression of the CCN family members Cyr61 from CTGF and Nov in human breast cancer. Endocr Relat Cancer 11: 781-791, 2004.
22. Brown L F, Papadopoulos-Sergiou A, Berse B et al: Osteopontin expression and distribution in human carcinomas. Am J Pathol 145: 610-623, 1994.
23. Bellahcene A and Castronovo V: Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am J Pathol 146: 95-100, 1995.
24. Tuck A, O'Malley F, Singhal H et al: Osteopontin expression in a group of lymph node-negative breast cancer patients. Int J Cancer 79: 502-508, 1998.
25. Chakraborty G, Jain S, Behera R et al: The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. Curr Mol Med 6(8): 819-830, 2006.